



The airway device laryngeal mask airway (LMA) is of 
importance during general anaesthesia as well as in emergency 
airway management. It came into clinical practice in 1988 
though it was first designed by Archie Brain in 1981.[1] 
Although propofol is the drug of choice for induction during 
LMA insertion because of its depressant effect on airway 
reflexes, propofol alone at the recommended induction dose 
of 1.5–2.5 mg/kg does not always guarantee successful 
LMA insertion. The total amount of propofol required to 
ease insertion and prevent reflex airway response when used 
alone exceeds 3.0 mg/kg.[2] This increases the incidence of 
dose‑related side effects such as hypotension, bradycardia, 
and apnea.[3] The insertion of LMA following induction with 
propofol in the absence of a muscle relaxant would require a 
depth of anaesthesia adequate enough to depress reflexes of the 
airway; the propofol dose to achieve that depth of anesthesia 
however, varies from one patient to another.[4]
Propofol is an alkylphenol derivative with a rapid onset of 
action, good recovery profile, and antiemetic effects. These 
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qualities make it a popular induction agent for short procedures 
and day-case surgeries. It has a distribution half-life of 
2–8 min[3] and induction of anaesthesia after a bolus dose occurs 
in 30–45 s, which is one-arm brain circulation time. The time 
to peak effect (as assessed by bispectral index) is 1.5 min.[3,5]
The loss of response to verbal command and loss of eyelash 
reflex is recognized as endpoints of propofol induction.[6] This 
endpoint, however, does not indicate an optimal anaesthetic 
state that yields a smooth LMA insertion, resulting in reflex 
airway responses. A lesser induction dose of propofol can be 
achieved by the addition of other agents such as midazolam, 
ketamine, low-dose muscle relaxants, and opioids, thus 
reducing undesired effects such as hypotension, respiratory 
depression, and reflex airway responses.[6-8]
Suxamethonium, a depolarizing muscle relaxant, at a low 
dose (0.1 mg/kg), has been found to suppress laryngeal 
reflexes by depolarization of motor end‑plate,[9] thus lessening 
the amount of propofol required to achieve LMA insertion. 
It has a rapid onset and offset of action. It decreases the 
incidence of coughing and gagging without causing full muscle 
paralysis.[10] Low‑dose suxamethonium has no significant effect 
on spontaneous ventilatory effort and repeated doses do not 
cause bradycardia.[11]
This research work was aimed at evaluating the effect of 
suxamethonium at a dose of 0.1 mg/kg on propofol dose 
used for LMA insertion, its effect, and related postoperative 
complications in adult patients undergoing general anaesthesia 
in our setting.
Methodology
This was a randomized single-blinded clinical study 
prospectively performed in a tertiary institution in North 
West Nigeria. With the hospital ethics committee approval, 
we obtained informed consent from 80 American Society 
of Anaesthesiologist status classification I and II patients 
aged between 18 and 60 years. In-patients eligible for the 
study were routinely reviewed a day before the scheduled 
surgery on the ward by the investigator and day-care patients 
were evaluated for inclusion in the study on the morning of 
surgery. Patients who are known to have hypersensitivity 
to propofol or suxamethonium, family history of plasma 
cholinesterase deficiency, neuromuscular disorders, family 
history of malignant hyperthermia, restricted mouth opening 
(inter‑incisor gap ˂2.5 cm), cervical spine disease, at risk of 
aspiration, undergoing oral or nasal surgery, obese with body 
mass index >35 kg/m2, taking sedative drugs, and with failed 
LMA insertion were excluded.
A formula used to determine the appropriate sample size for the 
study showed that a minimum of 72 patients were required.[12] 
Allowing for an estimated 10% nonconsent or dropout rate, the 
total sample size for the 2 groups was 80 patients.
Patients enrolled in the study were randomly allocated into one 
of two groups. Eighty pieces of uniformly sized sheets of paper 
were labelled P or S (40 each), representing groups P (placebo) 
and group S (suxamethonium), respectively. These papers 
were folded and shuffled in a large box. Each patient picked 
one folded sheet of paper from the box and handed it over to 
the research assistant. The patient’s hospital file number was 
written on a sheet of paper and sealed in a separate envelope 
that was only opened after completion of the study. The 
investigator was blinded to the study drug.
The study drug (suxamethonium 0.1 mg/kg) and placebo 
(0.9% saline) were prepared in identical 5-ml syringes, by 
the research assistant according to the patient’s group, while 
the investigator remained blinded. The study drug had the 
same appearance (colourless) as the placebo, made up to 
equal volumes of 5 ml, and the content of each syringe was 
not disclosed to the investigator. The initial dose of propofol 
based on body weight was prepared in a 20-ml syringe. Another 
preparation was made inside a 10-ml syringe for rescue doses. 
Lidocaine 1% was added to propofol in a 1:10 ratio to minimize 
injection pain.
On arrival in the operating room, the patient was positioned 
supine on the operating table and baseline vital signs which 
include noninvasive systolic and diastolic blood pressures 
(SBPs and DBPs), mean arterial pressure (MAP) blood, 
pulse rate (PR), respiratory rate, peripheral arterial oxygen 
saturation of haemoglobin (SpO2), and electrocardiograph 
were obtained. An intravenous access was secured using 
an 18G cannula and 0.9% saline infusion was commenced. 
The LMA classic TM (TeleflexR) was used in all patients of 
either group. The size of LMA was chosen based on patients’ 
weight as recommended by the manufacturer.[1] These patients 
were scheduled for short elective surgeries (in-patients and 
day-surgery cases) under general anaesthesia with LMA as 
the airway device of choice.
Patients were preoxygenated with 100% oxygen at the 
rate of 5–6 L/min for 3–5 min using a Bain circuit with a 
tight‑fitting facemask. The LMA was prepared by pressing 
the concave part of the mask against a hard surface and its 
cuff was deflated. The back of the mask was then lubricated 
using K-Y Jelly. All patients were induced with 2.5 mg/kg 
intravenous 1% propofol injected continuously over 30 s by 
the research assistant. The adequacy of induction was assessed 
30 s later (i.e., 60 s after the start of propofol injection) by loss 
of response to verbal command (open your eyes) the amount 
of propofol injected was noted. The patients immediately 
then received either 5 ml of 0.9% saline in group P or 5 ml of 
low-dose suxamethonium, the investigator then assessed for 
adequacy of mouth opening 30 s after administration of the 
study drug or placebo. If there was an inability to open the 
mouth or inadequate mouth opening (jaw not relaxed), a bolus 
dose of 0.5 mg/kg propofol was given to deepen anesthesia 
and a reassessment was done 30 s later.
When mouth opening was adequate, the patient’s head was 
extended and the neck was flexed on the chest (sniffing position). 
The LMA was grasped like a pen in the dominant hand, with the 
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tip of the index finger at the junction of the mask and tube. It 
was inserted into the mouth and advanced until resistance was 
felt. The cuff was then inflated with an appropriate volume of air 
until the LMA tube was seen to rise slightly out of the patient’s 
mouth. If mouth opening was adequate but correct positioning 
after insertion was not achieved because of severe airway 
response, or head or body movement, the LMA was removed. 
A dose of 0.5 mg/kg of propofol was administered to deepen 
anaesthesia and reinsertion was attempted 30 s later. Not more 
than three attempts at insertion were permitted for the study. In 
between insertion attempts, the patients were ventilated via a 
facemask with 100% oxygen devoid of volatile agents at a flow 
rate of 5–6 L/min. If LMA insertion was to be unsuccessful after 
three attempts, the patient’s airway would have been secured 
with an appropriate-sized endotracheal tube. This was termed 
as a failure of LMA insertion and the patient would have been 
excluded from the study.
Following successful insertion of the LMA, the patient was 
connected to the anaesthesia machine via the Bain circuit. 
Correct LMA placement was ascertained by auscultation for 
bilaterally equal air entry and square wave form on capnograph 
trace in spontaneously breathing patients or during assisted 
breaths in patients with apnea. If correctly placed, the LMA was 
then secured with adhesive tape. Anaesthesia was maintained 
on 1%–2% minimum alveolar concentration isoflurane in 50% 
oxygen in air at a total fresh gas flow rate of 5–6 L/min. The total 
dose of propofol injected was recorded. The haemodynamic 
changes (SBP, DBP, MAP, and PR) were recorded before 
induction of anaesthesia and 0, 1, 3 and 5 min after the insertion 
of LMA. Any incidence of hypotension, bradycardia, and apnea 
was noted and treated accordingly. Hypotension was defined 
as more than 30% decrease in baseline SBP, while bradycardia 
was defined as more than 30% decrease in baseline PR. Apnea 
was defined as cessation in breathing, as evidenced by absence 
of chest movement, from the end of propofol injection. The 
duration of apnea, defined as the time from successful LMA 
insertion till return of spontaneous breathing, was noted. 
Assisted ventilation was to be given to apneic patients (with 
SpO2 below 90%) through the LMA to maintain SpO2 above 
95% and end-tidal carbon dioxide concentration between 35 
and 45 mmHg till resumption of spontaneous breathing.
The end points were considered to be when the patient was 
able to make appropriate tidal volume, and when tidal volumes 
were stable enough and comparable to the baseline values. No 
further intraoperative anesthetic management was influenced 
by the study. Protocol for the management of anticipated 
adverse effects is as follows:
Hypotension: Intravenous ephedrine 3 mg
Bradycardia: Intravenous atropine 0.01 mg/kg
Desaturation: 100% oxygen via face mask at 5–6 L/min.
The data obtained were recorded on the preformed data 
collection form. Data entry was done by two separate clerical 
staff and was further cross‑checked for consistency.
The data obtained were analyzed using Statistical Package for the 
Social Sciences (SPSS is a software package used for statistical 
analysis produced by SPSS Incorporated and acquired by IBM 
in 2009) version 21.0. Quantitative variables such as age, weight, 
height, total propofol requirement per kilogram body weight, and 
the duration of apnea were summarized using mean (± standard 
deviation) and compared using independent t-test. Qualitative 
variables such as the incidence of apnea were summarized using 
percentages and compared using Chi-squared test or Fisher’s test.
results
Table 1 shows the demographic profile of patients in the 
two groups, and the results were comparable. There was no 
statistically significant difference between the two groups with 
respect to age, weight, and sex distribution.
The mean tota l  propofol  consumed in  group P, 
186.15 ± 24.04 mg, was significantly higher than in group S, 
174.00 ± 24.89 mg (P = 0.029). The mean dose of propofol per 
body weight used in group P (3.13 ± 0.49 mg/kg) was significantly 
higher than in group S (2.82 ± 0.39 mg/kg) (P = 0.002). The 
mean duration of apnea in group P (1.04 ± 1.26 min) was longer 
than in group S (0.65 ± 0.85 min), but there was no statistically 
significant difference (P = 0.107) [Table 2].
Both systolic and DBPs showed no significant statistical 
difference for both groups S and P at the different study timings 
[Tables 3 and 4]. Post-insertion of the LMA, the mean SBP of 
patients in both groups was comparable (P = 0.709, P = 0.351, 
P = 0.707, and P = 0.617 at 0, 1, 3 and 5 min post insertion, 
respectively). The mean DBP of patients in group P was higher 
than those in group S at 0, 1, 3 and 5 min post-insertion of the LMA, 
but the differences were not statistically significant (P = 0.124, 
P = 0.471, P = 0.251, and P = 0.338, respectively).
Table 5 shows the mean MAP changes at different time intervals 
in the two groups; the mean MAP of patients in group P was 
comparable with those in group S (P = 0.927, P = 0.767, P = 0.645, 
and P = 0.612 at 0, 1, 3 and 5 min post-insertion, respectively).
Table 6 shows the mean PR changes at different time intervals 
in the two groups. At all study timings post insertion of the 
LMA, the mean PR of patients in group P was lower than 
those in group S. However, the difference was not statistically 
significant (P = 0.731, P = 0.138, P = 0.082, and P = 0.112 at, 
0, 1, 3 and 5 min post insertion, respectively).
Table 1: Patients’ demographic data and clinical 
characteristics
Group P (n=40) Group S (n=40) P
Age (years) 38.40±14.01 35.55±14.01 0.319
Weight 60.50±6.87 61.90±6.83 0.364
BMI (kg/m2) 22.00±1.50 22.08±2.29 0.863
Gender (male: female) 18:22 26:14 0.072
ASA (I: II) 34:6 31:9 0.390
Interincisor gap (cm) 7.13±0.82 6.75±1.08 0.085
BMI: Body mass index
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Table 4: Changes in mean diastolic blood pressure at 
different time intervals
DBP (mmHg) Mean±SD P
Group P Group P
Baseline 78.50±6.44 78.20±9.32 0.867
After LMA insertion (min)
0 66.50±7.19 65.40±8.69 0.124
1 63.20±8.14 61.60±11.35 0.471
3 63.60±10.47 60.60±12.65 0.251
5 65.80±7.74 64.00±8.91 0.338
DBP: Diastolic blood pressure, LMA: Laryngeal mask airway, SD: 
Standard deviation
Table 3: Changes in mean systolic blood pressure at 
different time intervals
SBP (mmHg) Mean±SD P
Group P Group S
Baseline 131.00±4.22 131.90±6.83 0.481
After LMA insertion (min)
0 113.60±9.61 114.40±9.49 0.709
1 108.70±9.69 106.60±10.32 0.351
3 108.70±12.49 107.00±11.18 0.707
5 110.70±11.98 109.40±11.17 0.617
SBP: Systolic blood pressure, LMA: Laryngeal mask airway, SD: 
Standard deviation
Table 2: Induction characteristics of patients
Mean±SD P
Group P Group S
Initial bolus propofol (mg) 152.50±15.73 155.00±18.08 0.511
Additional propofol given (mg) 34.65±24.81 17.75±21.24 0.002*
Mean total propofol consumed (mg) 186.15±24.04 174.00±24.89 0.029*
Mean dose of propofol used (mg/kg) 3.13±0.49 2.82±0.39 0.002*
Mean duration of apnea (min) 1.04±1.26 0.65±0.85 0.107
SD: Standard deviation
Table 5: Changes in mean arterial pressure at different 
time intervals
MAP (mmHg) Mean±SD P
Group P Group S
Baseline 96.40±4.60 96.50±7.51 0.943
After LMA insertion (min)
0 82.60±6.71 82.40±12.12 0.927
1 78.60±8.33 78.00±9.68 0.767
MAP: Mean arterial pressure, LMA: Laryngeal mask airway, SD: 
Standard deviation
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At all study timings post insertion of the LMA, the mean SpO2 
of patients in group P was comparable to those in group S 
and the difference was not statistically significant (P = 0.245, 
P = 0.632, P = 0.129, and P = 0.386 at 0, 1, 3 and 5 min post 
insertion, respectively) [Table 7].
Figure 1 shows the incidence of drug side effects 
(apnea, hypotension, and bradycardia) in both study groups. 
Apnea was observed in 20 patients (50.0%) in group P and 
23 patients (57.5%) in group S. The difference was not 
statistically significant (P = 0.501). There was no incidence 
of hypotension or bradycardia (30% or more drop in MAP and 
PR respectively) in the two study groups.
Apnea was observed in 20 patients (50.0%) in group P and 
23 patients (57.5%) in group S. The difference was not 
statistically significant (P = 0.501). The mean duration of 
apnea was 1.04 min in group P and 0.65 min in group S; the 
difference was not statistically significant (P = 0.107).
dIscussIon
In order to avoid complications such as laryngeal spasm, 
gaging and coughing during insertion of LMA, optimal 
conditions are required; these include a sufficient mouth 
opening with suppression of airway reflexes and a relaxed jaw.
The findings from this study showed that following propofol 
induction, suxamethonium at 0.1 mg/kg significantly reduced 
the required propofol dose appropriate for insertion of LMA. 
We found that the initial propofol requirement based on 
the standard induction dose of 2.5 mg/kg was similar in 
the two groups, P = 0.511. However, additional propofol 
requirement as seen in patients that received suxamethonium 
was significantly less than those that received the placebo, 
P = 0.002. Consequently, the mean dose of propofol 
required before successful LMA insertion was less in the 
suxamethonium group (2.82 mg/kg) compared to the placebo 
group (3.13 mg/kg), P = 0.002. This result is consistent with 
the findings from other studies.[9,13,14]
Aghamohammadi et al.[13] reported that the number of patients 
that required additional propofol before successful LMA 
insertion in their suxamethonium group (10%) was significantly 
lower compared to that (53%) in the placebo group, P = 0.001. 
Similarly, Jain and Parikh[14] found a significant reduction in 
the dose of propofol required for insertion of the LMA in the 
propofol plus suxamethonium group (2.66 mg/kg) compared 
to the propofol-only group (3.1 mg/kg), P < 0.01.
On the contrary, Salem[6] did not find any significant 
difference in the propofol requirement in the group that had 
suxamethonium compared to the placebo group, P > 0.05. This 
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Table 7: Changes in mean oxygen saturation at different 
time intervals
SPO2 (%) Mean±SD P
Group P Group S
Baseline 99.80±0.41 99.65±0.48 0.136
After LMA insertion (min)
0 99.50±0.51 99.58±0.76 0.245
1 98.90±0.96 99.00±0.91 0.632
3 97.40±2.41 98.10±1.60 0.129
5 98.00±1.92 98.30±1.02 0.386
SPO2: Oxygen saturation, LMA: Laryngeal mask airway, SD: Standard 
deviation
Table 6: Changes in mean pulse rate at different time 
intervals
PR (beats/min) Mean±SD P
Group P Group S
Baseline 82.40±8.54 81.30±8.24 0.559
After LMA insertion (min)
0 97.30±10.80 98.20±12.43 0.731
1 94.30±11.90 98.20±11.37 0.138
3 94.80±13.74 99.70±10.95 0.082
5 92.70±12.33 96.60±9.16 0.112
LMA: Laryngeal mask airway, PR: Pulse rate, SD: Standard deviation
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is likely because patients who required more than one attempt 
at insertion in his study were kept anaesthetized with isoflurane 
unlike the additional propofol doses used in this present study.
In this study, a reduction from baseline SBP, DBP, and MAP 
and a rise in PR were observed at all study timings post-LMA 
insertion in both study groups. This conforms to the report 
of Jamil et al.[9] who observed a drop in MAP and a rise in 
PR from baseline at all study timings in both the placebo 
and suxamethonium groups. Furthermore, despite the higher 
propofol consumption in the placebo group compared to the 
suxamethonium group (P = 0.029), the MAP at the, 0, 1, 3 and 
5 min in the two groups was comparable, P = 0.927, 0.767, 
0.645, and 0.612, respectively. This could be explained by 
the fact that the higher number of patients requiring extra 
doses of propofol in the placebo group might have had airway 
responses to initial LMA insertion resulting in a pressor effect 
that attenuated the hypotensive changes that comes with 
propofol induction.
Contrary to the finding in this study, Ho and Chui[15] reported 
that the mean reduction in the MAP within the first 5 min of 
insertion was more profound in the placebo group compared 
to the suxamethonium group. The explanation for this is likely 
due to the recruitment of the elderly patients in their placebo 
group compared to the suxamethonium group. Elderly subjects 
are more prone to the cardiodepressant effect of propofol than 
middle-aged or young adults.[16] Also, a rescue propofol dose 
of 1 mg/kg was used in their study rather than the 0.5 mg/kg in 
this present study, which might have been responsible for more 
drops in the MAP. However, there was no significant difference 
in the changes in heart rate between the two groups (P > 0.05).
George et al.[17] also found that haemodynamic changes after 
insertion of the LMA in patients who received either placebo, 
suxamethonium 0.1 mg/kg, or 0.25 mg/kg following propofol 
induction were similar.
In this study, none of the patients in both study groups 
developed severe hypotension or bradycardia. This is similar 
to the report of Jain and Parikh.[14] George et al.,[17] however, 
noted 9.2% of patients developed hypotension that required 
a vasopressor. This could be attributed to the fentanyl 
pretreatment given to their patients, which potentiates the 
cardiorespiratory depressant effect of propofol.[16]
The SpO2 values in both study groups in the current study were 
found relatively unchanged at all study timings post-LMA 
insertion. This is consistent with the report of Jain and 
Parikh.[14] Salem, however, noted a trend toward reduction 
in SpO2 from baseline values post LMA insertion. Although 
their patients were preoxygenated and their apnea periods 
were similar to those recorded in this study, they were kept 
oxygenated in between insertion attempts with oxygen from an 
isoflurane–nitrous oxide mixture rather than the 100% oxygen 
used in this study.
Duration of action of suxamethonium is dose-dependent; 
reducing the dose allows a more rapid return of spontaneous 
ventilation and airway reflexes.[18] In this study, a higher 
incidence of apnea occurred in the suxamethonium group 
compared to the placebo group, though the difference was 
not significant, P = 0.501. However, the mean duration of 
apnea was shorter in the suxamethonium group compared to 
Figure 1: Incidence of drug side effects during laryngeal mask airway 
insertion
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the placebo group, but the difference was also not significant, 
P = 0.107. Similarly, Ho and Chui[15] did not find any significant 
difference in the duration of apnea between the suxamethonium 
and placebo groups, P = 0.46. The incidence of apnea recorded 
by Jain and Parikh[14] in their propofol plus suxamethonium 
group (84%) and the propofol-only group (80%) is higher 
than those (57.5% and 50%, respectively) obtained in this 
study. This is likely due to the higher suxamethonium dose 
(0.25 mg/kg) used in their study.
Contrary to the finding in this study, Jamil et al.[9] reported a 
significantly higher incidence of apnea in the placebo group 
compared to suxamethonium group, P < 0.05. The difference 
in propofol consumption in their two study groups (0.7 mg) 
was wider than that observed in this study (0.31 mg). That 
difference might have accounted for the significantly higher 
incidence of apnea in their placebo group.
conclusIon
Suxamethonium (0.1 mg/kg) following induction reduced 
propofol consumption for LMA insertion. The haemodynamic 
responses following LMA insertion using propofol combined 
with suxamethonium (0.1 mg/kg) were well controlled and 
comparable to when propofol is used as a sole induction 
agent. The duration of apnea is reduced in patients that receive 
low-dose suxamethonium, but the incidence of apnea is similar 
between the two study groups.
Recommendation
Suxamethonium is a readily available drug and its role in the 
significant reduction of induction dose of propofol, while using 
LMA makes it desirable and is recommended for use.
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